pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,551 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1049Endpoints793BioPharma Dive305BioSpace227Fierce Biotech215onclive165raps82globenewswire health
therapy area
allOncology6216Rare Disease1502Cardiology1123Hematology1060Immunology1035Vaccines939Pulmonology
  • Biotech firms raise record funds in 2026, with $2.1 bn round for Isomorphic Labs
    After a few slow years, the biotech financing landscape is showing signs of recovery, though investors remain cautious about where they place capital. A recent PharmaVoice reader poll found that 2…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • Anthropic launches Claude Science, AI platform aimed at bioscience and drug discovery
    Anthropic, known for its Claude Code AI coding assistant, announced a new product called Claude Science aimed at the life‑science sector. The platform is designed to help biopharma researchers wit…
    Endpoints · 1mo agoPositive↗ source
← prev
page 34 of 63
next →
73
fda recalls51
fda medwatch45
fda press28
923
Psychiatry & CNS741
Ophthalmology437
Pain417
Endocrinology & Metabolism395
Infectious Disease374
  • Health tech executives grow confident in AI, survey shows sharp shift in attitudes
    A yearly survey conducted by Venrock partners Bob Kocher, Bryan Roberts and Siobhan Nolan Mangini reveals that confidence in using artificial intelligence within healthcare has risen sharply over t…
    Endpoints · 1mo agoPositive↗ source
  • Virtual mental-health firms accelerate AI chatbot development using therapy session data
    People are turning to artificial intelligence for daily tasks, companionship and emotional support, prompting virtual mental‑health providers to explore AI solutions. Companies that were previousl…
    Endpoints · 1mo agoNeutral↗ source
  • FDA acting director of cell and gene therapies Vijay Kumar to depart his post
    Vijay Kumar, who has been serving as the acting director of the Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products, announced he will leave his position. In an inte…
    Endpoints · 1mo agoNeutral↗ source
  • Nominations Open for 2026 Endpoints 11 Biotech Awards
    Nominations for the 2026 Endpoints 11 awards are now being accepted, with submissions due by July 15. The awards target private biotech startups that have differentiated science, strong leadership…
    Endpoints · 1mo agoNeutral↗ source
  • NEJM retracts pivotal data for Amgen's Tavneos, adding new hurdle for the autoimmune drug
    The New England Journal of Medicine has withdrawn the pivotal data that supported Amgen’s autoimmune therapy Tavneos. The retraction was requested by two academic authors who raised concerns about…
    Endpoints · 1mo agoNegative↗ source
  • Zymeworks CEO says $1 billion Theravance acquisition offers strong value despite recent setbacks
    Zymeworks chief executive Kenneth Galbraith explained why the company believes its near-$1 billion purchase of Theravance makes strategic sense. He noted that Theravance has faced operational diff…
    Endpoints · 1mo agoDealPositive↗ source
  • Evommune's lead drug fails in chronic hives trial, shares tumble over 30%
    Evommune reported its first major trial readout since going public last year, focusing on its lead candidate for chronic spontaneous urticaria, a condition where patients experience recurring hives…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • Talawar Therapeutics merges with JATT II Acquisition to list on Nasdaq as AstraZeneca reports Phase 3 success in pediatric bone disease
    Talawar Therapeutics announced a combination with blank‑check company JATT II Acquisition Corp, a deal that will place Talawar on the Nasdaq exchange. The SPAC transaction gives Talawar public‑mar…
    Endpoints · 1mo agoDealPositive↗ source
  • Chinese partnerships are becoming the pharma industry's new tax inversion strategy
    The article notes that a decade after the wave of U.S. tax inversions, the pharmaceutical sector is now seeing a similar pattern with deals involving Chinese entities. Analysts argue that these tra…
    Endpoints · 1mo agoDealNeutral↗ source
  • BioCryst to shut internal drug discovery and close Alabama research site
    BioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts. The company said it will seek future programs through external collaborations rather than in‑house resear…
    Endpoints · 1mo agoNegative↗ source
  • J&J EVP John Reed Discusses R&D Model, Oncology Deals and Pipeline Growth Potential
    John Reed, executive vice president of Innovative Medicine at Johnson & Johnson, brings more than a decade of experience overseeing drug pipelines at three of the world’s largest pharmaceutical com…
    Endpoints · 1mo agoNeutral↗ source
  • Over 200 biopharma investors urge EU governments to strengthen Europe's life-science sector
    More than 200 biopharma investors and companies have signed an open letter addressed to EU member states, calling for action to improve Europe's life‑science sector. The signatories argue that Eur…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Theravance, after clinical setbacks, agrees to $929M buyout
    The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
    BioPharma Dive · 1mo ago↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 1mo ago↗ source
  • 10 clinical trials to watch in the second half of 2026
    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
    BioPharma Dive · 1mo ago↗ source
  • FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
    Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
    BioPharma Dive · 1mo ago↗ source
  • At BIO, tension over China biotech deal regulation looms
    Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.
    BioPharma Dive · 1mo ago↗ source
  • Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
    Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
    BioPharma Dive · 1mo ago↗ source
  • On second try, Acadia drug gets nod from European regulators
    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
    BioPharma Dive · 1mo ago↗ source
  • De-Risking a Rare Disease Launch Starts with Precision
    Why traditional models fall short in rare disease commercialization—and what works instead.
    Fierce Biotech · 2mo ago↗ source
  • Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more
    Welcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…
    Endpoints · 2mo ago↗ source
  • Endpoints News History: 10 Years, Bootstrap to FT
    Ten years of Endpoints News: no investors, a 50/50 split, profitable from day one. Co-founders Arsalan Arif and John Carroll on how the partnership held.
    Endpoints · 2mo ago↗ source
  • US government launches probe into Germany's plan to pay less for drugs
    Amid Germany's ongoing review of its healthcare spending, the US government has started a trade investigation into the European country's drug pricing system. The investigation, under Section 301 o…
    Endpoints · 2mo ago↗ source